CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

This study is testing CAR-T cell therapy using cells engineered to target a protein called CD7, found on T-cell lymphoma and leukemia cells, in people whose cancer has come back or stopped responding to standard treatments. **You may be eligible if...** - You are between 18 and 75 years old with confirmed relapsed or refractory T-cell lymphoma or leukemia - Your cancer has failed initial treatment or relapsed after achieving remission - Your general health score is 0–2 and expected survival is more than 3 months - You have no contraindications to the blood cell collection procedure - You have not received antibody therapy in the 2 weeks before cell therapy **You may NOT be eligible if...** - You are allergic to any component of the cell product - Your liver function, kidney function, or platelet count is below the required threshold - You have severe heart failure (Class III or IV) - Your blood oxygen level or lung function is significantly impaired Talk to your doctor to see if this trial is right for you.